

Joachim G J V Aerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/795484/publications.pdf>

Version: 2024-02-01

106
papers

4,305
citations

172207

29
h-index

128067

60
g-index

106
all docs

106
docs citations

106
times ranked

6288
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes. <i>Annals of the American Thoracic Society</i> , 2022, 19, 551-561.	1.5	33
2	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
3	Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition. <i>Lung Cancer</i> , 2022, 165, 91-101.	0.9	5
4	Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. <i>Thorax</i> , 2022, 77, 1260-1267.	2.7	11
5	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 204.	2.4	12
6	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. <i>European Journal of Cancer</i> , 2022, 165, 195-204.	1.3	5
7	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	5.1	25
8	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <i>PD-L1</i> $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
9	Home monitoring of lung function, symptoms and quality of life after admission with <i>COVID-19</i> infection: The 'HOMECOMIN' study. <i>Respirology</i> , 2022, 27, 501-509.	1.3	9
10	Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2595-2595.	0.8	0
11	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2002042.	3.1	28
12	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 467-475.	5.2	277
13	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 41-48.	1.3	64
14	Do-not-intubate status and COVID-19 mortality in patients admitted to Dutch non-ICU wards. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2207-2209.	1.3	8
15	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1005.	1.0	23
16	Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100155.	0.6	3
17	Genetic polymorphism in <i>ATIC</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. <i>Thorax</i> , 2021, 76, 1150-1153.	2.7	4
18	Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 2618-2618.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. <i>Vaccines</i> , 2021, 9, 525.	2.1	13
20	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. <i>Lung Cancer</i> , 2021, 155, 53-60.	0.9	8
21	Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21135-e21135.	0.8	0
22	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
23	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
24	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
25	Re: Comments on "High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients". <i>European Journal of Cancer</i> , 2021, 153, 267-269.	1.3	1
26	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2970-2987.	1.3	11
27	Analyzing high-dimensional cytometry data using FlowSOM. <i>Nature Protocols</i> , 2021, 16, 3775-3801.	5.5	79
28	CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge. <i>BMC Health Services Research</i> , 2021, 21, 847.	0.9	18
29	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	1.7	10
30	Experiences of healthcare professionals with support for mesothelioma patients and their relatives: Identified gaps and improvements for care. <i>European Journal of Cancer Care</i> , 2021, 30, e13509.	0.7	2
31	In Response to "Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision Making: A New Way of Counting". <i>JTO Clinical and Research Reports</i> , 2021, 2, 100215.	0.6	0
32	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 44-49.	0.9	1
33	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. <i>Translational Lung Cancer Research</i> , 2020, 9, 1169-1179.	1.3	30
34	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
35	Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. <i>EBioMedicine</i> , 2020, 62, 103040.	2.7	35
36	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 400-410.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. <i>Lung Cancer</i> , 2020, 146, 341-349.	0.9	3
38	A brief report on combination chemotherapy and anti-“programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. <i>European Journal of Cancer</i> , 2020, 137, 40-44.	1.3	5
39	Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. , 2020, 8, e001193.		28
40	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3179.	1.7	11
41	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1472-1483.	0.5	32
42	T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. , 2020, 8, e000251.		19
43	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
44	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
45	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
46	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
47	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	2.4	57
48	Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. <i>Frontiers in Oncology</i> , 2020, 10, 343.	1.3	48
49	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035.	2.0	5
50	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 393-401.	2.5	79
51	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. <i>ERJ Open Research</i> , 2020, 6, 00054-2020.	1.1	17
52	Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. <i>Genes</i> , 2020, 11, 358.	1.0	0
53	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 771-777.	2.0	70
54	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4

#	ARTICLE	IF	CITATIONS
55	Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 3074-3074.	0.8	5
56	IMpower150: Exploratory analysis of brain metastases development.. Journal of Clinical Oncology, 2020, 38, 9587-9587.	0.8	8
57	Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.. Journal of Clinical Oncology, 2020, 38, 51-51.	0.8	1
58	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
59	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENDritic cell Immunotherapy for Mesothelioma (DENIM) trial. Translational Lung Cancer Research, 2019, 8, 280-285.	1.3	46
60	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1276.	3.4	670
61	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
62	Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. British Journal of Cancer, 2019, 121, 372-377.	2.9	12
63	Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. Annals of Surgical Oncology, 2019, 26, 4222-4228.	0.7	16
64	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. European Heart Journal, 2019, 40, 3901-3909.	1.0	54
65	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Respiratory Medicine, 2019, 154, 27-33.	1.3	4
66	Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open, 2019, 9, e026779.	0.8	11
67	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Molecular Therapy - Oncolytics, 2019, 13, 67-81.	2.0	44
68	Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 175-182.	1.4	5
69	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. ERJ Open Research, 2019, 5, 00179-2019.	1.1	20
70	Correlation between nivolumab exposure and treatment outcomes in non-“small-cell lung cancer. European Journal of Cancer, 2019, 109, 12-20.	1.3	58
71	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-“small Cell Lung Cancer Patients. Clinical Cancer Research, 2019, 25, 2219-2227.	3.2	32
72	The clinical impact of <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis in a Dutch referral centre. European Respiratory Journal, 2019, 53, 1802081.	3.1	7

#	ARTICLE	IF	CITATIONS
73	Immunotherapy: a new standard of care in thoracic malignancies?. European Respiratory Journal, 2018, 51, 1702072.	3.1	11
74	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. British Journal of Cancer, 2018, 118, 1296-1301.	2.9	49
75	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research, 2018, 24, 766-776.	3.2	68
76	Biomarkers in malignant mesothelioma—“an unfulfilled need or a waste of resources?”. Journal of Thoracic Disease, 2018, 10, S1084-S1087.	0.6	4
77	Circulating desmosine as a biomarker of azithromycin treatment response: a <i>post hoc</i> analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018.	1.1	0
78	Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?. Frontiers in Immunology, 2018, 9, 2804.	2.2	94
79	Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. Frontiers in Immunology, 2018, 9, 2759.	2.2	58
80	Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS. Frontiers in Immunology, 2018, 9, 2034.	2.2	10
81	Low-dose cyclophosphamide depletes circulating na ⁺ ve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. OncoImmunology, 2018, 7, e1474318.	2.1	30
82	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences, 2018, 19, 1041.	1.8	53
83	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. Chest, 2018, 154, 798-807.	0.4	42
84	Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clinical and Experimental Metastasis, 2018, 35, 625-633.	1.7	28
85	Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. Frontiers in Oncology, 2018, 8, 159.	1.3	15
86	Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.. Journal of Clinical Oncology, 2018, 36, 9023-9023.	0.8	46
87	Correlation between nivolumab exposure and treatment outcome in NSCLC.. Journal of Clinical Oncology, 2018, 36, 9057-9057.	0.8	1
88	Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. Lung Cancer, 2017, 107, 36-40.	0.9	18
89	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Immunotherapy, 2017, 9, 507-520.	1.0	12
90	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncology, The, 2017, 18, 1261-1273.	5.1	356

#	ARTICLE	IF	CITATIONS
91	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 5-15.	3.2	48
92	Thyroid Function and Cancer Risk: The Rotterdam Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 5030-5036.	1.8	96
93	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 953-962.	0.8	365
94	Immune Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 59-90.	0.8	1
95	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. <i>Radiotherapy and Oncology</i> , 2016, 118, 442-446.	0.3	59
96	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. <i>Lung Cancer</i> , 2016, 92, 35-40.	0.9	15
97	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8502-8502.	0.8	26
98	Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: The NVALT-8 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8506-8506.	0.8	6
99	Iron deficiency anemia as initial presentation of a non-small cell lung carcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2015, 16, 109-111.	0.2	9
100	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. <i>Lung Cancer</i> , 2015, 88, 215-222.	0.9	58
101	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. <i>European Journal of Cancer</i> , 2015, 51, 893-903.	1.3	21
102	Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 88, 332-337.	0.9	22
103	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7506-7506.	0.8	10
104	Biomarkers for immune checkpoint inhibitors. <i>Lancet Oncology</i> , The, 2014, 15, e1.	5.1	4
105	Immunomodulation in cancer. <i>Current Opinion in Pharmacology</i> , 2014, 17, 17-21.	1.7	29
106	Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 361-368.	5.2	226